Optimizing Second-Line Therapy in CLL After Covalent BTK Inhibitor Exposure

Experts weigh mutation testing, comorbidities, and patient preference to guide second-line CLL options after BTK inhibitor resistance.

Experts discuss relapsed CLL workup, using PET-CT and lymph node biopsy to rule out Richter’s, plus resistance testing to guide next therapy.

Experts outline relapse workup in CLL, using PET-CT and biopsy for suspected Richter’s, plus resistance and TP53 testing to guide next therapy.

Phase 3 results: pirtobrutinib boosts PFS, delays next treatment after prior BTK therapy, and shows low cardiac toxicity.

Phase 3 data show pirtobrutinib extends PFS and delays next therapy after BTK inhibitors, with low atrial fibrillation and hypertension rates.

A 72-year-old CLL patient stops covalent BTK therapy due to AFib and hypertension; experts weigh switching BTK agents, pirtobrutinib, or venetoclax.

CLL therapy evolves fast: frontline trial updates, pirtobrutinib in second line, and BTK degraders promise simpler, better-tolerated options.